Rubius Therapeutics posts $48.5M loss in Q1; prioritizes on oncology and autoimmune products

CAMBRIDGE, Mass. – Rubius Therapeutics Inc. posted a loss of $48.5 million for the first quarter of 2020, or a loss of 60 cents per diluted share, the company reported Monday. The clinical-stage biopharmaceutical company, which has built a manufacturing facility in Smithfield, reported a loss of $32.6 million one year prior, or 42 cents…

Want More?

Subscribe or register with Providence Business News to keep reading.

REGISTER
for 2 more stories

Subscribe now for $1 for 4 weeks
Already a Subscriber? Login now

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -